Xvivo Perfusion AB
(OTCPK:XVIPF)
$
29
-0.39 (-1.32%)
Market Cap: 917.70 Mil
Enterprise Value: 898.67 Mil
PE Ratio: 119.15
PB Ratio: 4.07
GF Score: 91/100 Q1 2020 Xvivo Perfusion AB Earnings Call Transcript
Apr 09, 2020 / 09:30AM GMT
Release Date Price:
$10.05
Operator
Ladies and gentlemen, welcome to XVIVO Perfusion Report Webcast. I will now hand over to Magnus Nilsson, CEO. Please go ahead.
Magnus Nilsson;publ;MD;CEO
Xvivo Perfusion AB
()-&
Welcome to this 30th quarterly report of XVIVO Perfusion, the interim report January to March 2020. And I have with me Christoffer Rosenblad, the CFO. Christoffer?
Christoffer Rosenblad;publ;CFO
Xvivo Perfusion AB;Deputy CEO, Deputy MD & Board Secretary
()- -
Hello.
Magnus Nilsson;publ;MD;CEO
Xvivo Perfusion AB
()-&
Next slide, please. So first, the highlights of this very unusual Q1. We still have a strong cash position which is the primary message. So we have very limited cash consumption, cash consumption during Q1 in spite of a very heavy investment in R&D, as usual, and we end the quarter in a good financial position, SEK 159 million at the
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot